COVID-19 has created significant challenges for the Venture Capital (VC) market and life science companies seeking funding during the pandemic. While the pandemic has undoubtedly added a new layer of risk to an inherently risky field, the fundamentals for what makes a company attractive to a VC have remained steady.
Sara Nayeem, M.D. is a Partner at New Enterprise Associates (NEA), a large diversified venture capital firm. Sara joined NEA’s healthcare team in 2009 and focuses on investments in biopharmaceutical companies. She serves on the boards of Centrexion, Complexa, Cydan, Imara (IMRA), Tiburio, and a stealth targeted oncology company.
Top 10 Podcasts of 2019 from the BioHealth Capital Region Check out these Podcasts Featuring Some of the Top Biohealth Industry Leaders and Executives from the Region To say it [….]
Five Female Investors Who Are Making Their Mark in Life Science November 26, 2019 Less than 10% of decision-makers at U.S. venture capital (VC) firms are women and a whopping [….]
Maryland Biotech Just Raised $85 Million to Begin Clinicals for its Intelligent Cell Therapy Platform
Maryland Biotech Just Raised $85 Million to Begin Clinicals for its Intelligent Cell Therapy Platform With new funding, Arcellx furthers its cell therapy platform intended to address new therapies in [….]
Amita Shukla spoke this past January at Women in Bio – Capital Region on “Mastering the Entrepreneurial Mind: Leading Change that Changes the World”. Amita Shukla is a thought leader, innovator, and entrepreneur [….]